Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About

Trending Topics

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni

    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor & Employment
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations

    Industries

    View All

    • Cannabis
    • Consumer
    • Energy
    • Entertainment
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Non Profit
    • Real Estate
    • Technology

    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    1. Home
    2. Insights
    3. Alerts
    4. DOJ completes its first expedited antitrust review of collaborative efforts by businesses to respond to COVID-19Alerts

    Alert / Antitrust Alert

    DOJ completes its first expedited antitrust review of collaborative efforts by businesses to respond to COVID-19

    April 9, 2020

    Share

    By Brian Whittaker and Gordon Lang

    DOJ will not challenge collaborative efforts of medical supply distributors to expedite the provision of PPE to respond to COVID-19.  

    As we recently reported, the U.S. Federal Trade Commission (FTC) and Department of Justice (DOJ) announced an expedited antitrust procedure to provide guidance to businesses seeking to collaborate to protect the health and safety of Americans during the COVID-19 pandemic. Since then, some businesses have used the procedure and received quick guidance.

    On April 4, 2020, the DOJ issued a Business Review Letter[1] to multiple medical supplies distributors—McKesson Corporation, Owens & Minor Inc., Cardinal Health Inc., Medline Industries Inc., and Henry Schein Inc. The medical supplies distributors submitted a letter five days earlier, requesting an antitrust review of their collaborative efforts to expedite and increase manufacturing, sourcing, and distribution of medications and personal protective equipment (PPE), including masks, gowns, gloves, and other equipment intended to protect first responders and other medical professionals against infection while responding to the COVID-19 pandemic. The DOJ’s Business Review Letter explains its decision not to challenge those collaborative efforts.

    Collaborative efforts proposed by the medical supplies distributors

    The medical supplies distributors proposed to collaborate with, and at the direction of, federal agencies, particularly the Federal Emergency Management Agency (FEMA) and the U.S. Department of Health and Human Services (HHS), to:

    • Help address bottlenecks with our existing foreign suppliers
    • Help identify and qualify new sources of supply
    • Help identify and monitor areas of increased demand for supplies and medications
    • Help expedite the distribution of supplies and medications to FEMA-designated COVID-19 hotspots
    • Help understand competitive prices for these supplies and medications
    • Help negotiate competitive prices, through bilateral communication with FEMA
    • Provide FEMA and HHS with data necessary to do the activities identified above
    • Provide FEMA and HHS with claims data and data otherwise requested by FEMA
    • Help with other related activities to manufacture, source, and distribute medications and health care products as directed by FEMA, HHS, or additional government agencies

    Key aspects of the collaborative efforts

    The medical supplies distributors agreed to the following conditions with respect to their collaborative efforts:

    • They will not collaborate to fix prices, reduce output, reduce quality, or engage in profiteering.
    • They will take all reasonable efforts to ensure that any competitively sensitive business information requested by the federal government will not be shared with each other or competitors.
    • The proposed collaborative efforts are limited to the time period necessary to assist federal agencies in responding to PPE shortages resulting from the COVID-19 pandemic.

    Key reasons for DOJ’s decision

    • Most importantly, the DOJ concluded that the proposed collaborative efforts satisfy the general rule that the DOJ will not challenge conduct by private parties acting individually or together when “(i) the collaboration is compelled by an agreement with a federal agency or a clearly defined federal government policy and (ii) a federal agency supervises the conduct.” Therefore, it is significant that the medical supplies distributors will act pursuant to agreements with, and will be supervised by, the federal government.
    • The DOJ found that the proposed collaborative efforts likely do not raise competitive issues. The “procompetitive aspects of any arrangement far outweigh any potential harm” because the “proposed conduct is limited in scope and duration, necessary to address COVID-19-related scarcity, and will not extend beyond what is required to facilitate the availability of needed supplies.”
    • The DOJ also noted that the collaborative efforts might be subject to other antitrust exemptions and immunities. For example, the Noerr-Pennington doctrine will protect certain collaborative efforts related to petitioning the government, and “implied immunity” will protect certain collaborative efforts when application of the antitrust laws might “disrupt” or be “repugnant” to regulatory authority responding to the COVID-19 pandemic.

    Takeaways for other businesses

    • The DOJ’s Business Review Letter for the medical supplies distributors demonstrates that its expedited antitrust procedure can result in quick guidance in response to at least some COVID-19-related requests.
    • Businesses considering collaborative efforts to respond to COVID-19 should consult with antitrust counsel to evaluate whether they are consistent with antitrust laws and to consider whether a submission to the FTC or DOJ using the expedited review procedure would be appropriate.

    1. Available at https://www.justice.gov/atr/page/file/1266511/download (last visited Apr. 8, 2020).
      [Back to reference]

    Practices

    M&A and Corporate TransactionsPrivate Equity & Investment FundsSecurities & Capital MarketsGovernment Investigations & White Collar DefenseCongressional InvestigationsHealthcareAntitrustExport Controls & Economic Sanctions

    Industries

    Healthcare

    Insights And Happenings

    • Alert

      Interference or fair play? Congressional investigation into alleged politically motivated DOJ antitrust enforcement

      July 1, 2020
    • Alert

      The end of ACPERA?

      June 25, 2020
    • Alert

      PPE procurement considerations in light of recent DOJ criminal complaint against foreign mask manufacturer

      June 11, 2020

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • © 2023 Nixon Peabody. All rights reserved
    • Privacy Policy
    • Terms of Use
    • Statement of Client Rights
    • Supplier Diversity Program
    • Nixon Peabody International LLC
    • PAL